TY  - JOUR
A1  - Schmidt, Stanislaw
A1  - Tramsen, Lars
A1  - Schneider, Andreas
A1  - Schubert, Ralf
A1  - Balan, Ada
A1  - Degistirici, Özer
A1  - Meisel, Roland
A1  - Lehrnbecher, Thomas
T1  - Impact of human mesenchymal stromal cells on antifungal host response against Aspergillus fumigatus
T2  - OncoTarget
N2  - Mesenchymal stromal cells (MSCs) are increasingly given as immunotherapy to hematopoietic stem cell transplant (HSCT) recipients with refractory graft-versus-host disease (GvHD). Whereas the immunosuppressive properties of MSCs seem to be beneficial in GvHD, there is, at the same time, major concern that MSCs increase the risk for infection. We therefore investigated the interplay of human MSCs with Aspergillus fumigatus and the impact of MSCs on different arms of the anti-Aspergillus host response in vitro. Although A. fumigatus hyphae increase mRNA levels of IL6 in MSCs, the extracellular availability of IL-6 and other pro-inflammatory cytokines remains unaffected. Human MSCs are able to phagocyte Aspergillus conidia, but phagocytosis of conidia is not associated with an alteration of the cytokine production by MSCs. In addition, human MSCs do not affect activation and function of A. fumigatus specific CD4+ T cells, and MSCs do not negatively impact the oxidative burst activity of phagocytes. Our in vitro data indicate that administration of human MSCs is not associated with a negative impact on the host response against A. fumigatus and that the fungus does not stimulate MSCs to increase the release of those cytokines which play a central role in the pathophysiology of GvHD.
KW  - mesenchymal stromal cells
KW  - Aspergillus fumigatus
KW  - phagocytosis
KW  - hematopoietic stem cell transplantation
KW  - immunotherapy
Y1  - 2017
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/45182
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-451826
SN  - 1949-2553
N1  - All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
VL  - 8
IS  - 56
SP  - 95495
EP  - 95503
PB  - Impact Journals LLC
CY  - [s. l.]
ER  -